TransCode Therapeutics (RNAZ) reported Thursday the submission to the US Food and Drug Administration of an investigational new drug application amendment for a phase 2a trial with its lead therapeutic candidate, TTX-MC138. It is partnering with Quantum Leap Healthcare Collaborative.

Shares surged over 22% as intraday trading volume soared to over 11.3 million from a daily average of roughly 58,000.

Regal Rexnord (RRX) reported late Wednesday a year-over-year surge in Q4 revenue and adjusted earnings.

Shares jumped 13%, with intraday trading volume at over 3.1 million, compared with a daily average of about 806,000.

McKesson (MCK) late Wednesday reported fiscal Q3 adjusted net income and sales above market expectations, while revising up fiscal 2026 adjusted EPS guidance.

Shares jumped 18%, with intraday trading volume at over 1.46 million, compared with a daily average of about 705,000.

Price: 10.77, Change: +2.01, Percent Change: +22.95